Blog

Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair

Cambridge, MA, December 17, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that Michael Heffernan has joined the Board of Directors as Chairman.

“Indalo’s unique approach to treating fibrosis, combined with a highly experienced team and world-class financial backers, is poised to make a meaningful impact in serious fibrotic diseases,” commented Mr. Heffernan. “I look forward to working with the Indalo team as the company advances its compelling lead program and continues to expand its pipeline of integrin antagonists.”

Mr. Heffernan was most recently CEO of Collegium Pharmaceutical (COLL), a publicly traded pharmaceutical company that he founded and that is focused on developing and commercializing products for the treatment of chronic pain and related disorders. He also co-founded Avenge Bio, an immuno-oncology company that he is actively managing. He was previously CEO of Onset Dermatologics, a dermatology company that he founded and spun out of Collegium to create PreCision Dermatology, which was later sold to Valeant. Mr. Heffernan was previously Co-founder and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp, a public healthcare services company of which he later served as CEO and Chairman. Mr. Heffernan began his career at Eli Lilly, where he held a number of sales and marketing roles. He has recently served on the boards of TyRx (sold to Medtronic), Cornerstone Therapeutics (sold to Chiesi), PreCision Dermatology (sold to Valeant), and Ocata Therapeutics (sold to Astellas). He is currently Chairman of the board of Veloxis Pharmaceuticals (VELO) and Collegium Pharmaceutical (COLL) and is a member of the board of Akebia Therapeutics (AKBA) and Trevi Therapeutics (TRVI). He earned his B.S. degree in Pharmacy from the University of Connecticut.

Click here to read the entire press release.